4.7 Article

IRF4: Immunity. Malignancy! Therapy?

期刊

CLINICAL CANCER RESEARCH
卷 15, 期 9, 页码 2954-2961

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-08-1845

关键词

-

类别

资金

  1. National Institutes of Health (NIH)
  2. National Cancer Institute
  3. Center for Cancer Research

向作者/读者索取更多资源

IRF4, a member of the Interferon Regulatory Factor (IRF) family of transcription factors, is expressed in cells of the immune system, where it transduces signals from various receptors to activate or repress gene expression. IRF4 expression is a key regulator of several steps in lymphoid-, myeloid-, and dendritic-cell differentiation, including the differentiation of mature B cells into antibody-secreting plasma cells. IRF4 expression is also associated with many lymphoid malignancies, with recent evidence pointing to an essential role in multiple myeloma, a malignancy of plasma cells. Interference with IRF4 expression is lethal to multiple myeloma cells, irrespective of their genetic etiology, making IRF4 an Achilles' heel that may be exploited therapeutically.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据